Tag - alzheimers

 
Menu
Search
 
June 07, 2025
 

Today's print edition

Home Delivery
Subscribe for more access

ALZHEIMERS

A Japanese team has started a final-stage clinical trial to administer to patients with familial Alzheimer's disease a drug discovered using iPS cells.
JAPAN / Science & Health
Jun 4, 2025
Japanese team starts final-stage trial for iPS drug to treat Alzheimer's
Through the trial, which began in May, the team aims to confirm the safety and efficacy of the treatment, with hopes of obtaining regulatory approval.
The lack of quick and easy tests has until now slowed the rollout of new Alzheimer’s drugs.
WORLD / Science & Health
May 20, 2025
First blood test for Alzheimer’s to be available in U.S. in June
The test will initially be available at about 50 American research institutes and hospitals that specialize in Alzheimer’s disease.
A group of researchers including from Kyoto University confirmed that the TIM-3 protein, which exists in a type of immune cell in the brain, increases as the brain ages.
JAPAN / Science & Health
May 8, 2025
Loss of immune-regulating protein seen easing Alzheimer's disease
The findings are expected to help develop a new treatment for the disease.
In 2022, the number of elderly people with dementia in Japan reached 4.43 million, according to data from the health ministry.
JAPAN / Science & Health
Nov 28, 2024
Japan researchers develop a simple way to spot signs of Alzheimer's disease
The study showed that Alzheimer's disease can be predicted by identifying the "head-turning sign" in response to questions.
Lecanemab was developed by drugmakers Eisai of Japan and Biogen of the United States.
JAPAN / Science & Health
Nov 15, 2024
European agency switches to recommending new Alzheimer's drug
The committee judged that the efficacy of lecanemab outweighs the risk for some patients.
For patients using donanemab, it will cost them about ¥3.08 million per year. But national insurance coverage will have the government shoulder most of the cost.
JAPAN / Science & Health
Nov 13, 2024
Japan OKs insurance coverage of Alzheimer's drug donanemab
Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after lecanemab.
A scientist looks at brain scans of a patient suffering from Alzheimer's disease in Geneva in 2023.
WORLD / Science & Health
Sep 21, 2024
Revolution or mirage? Controversy surrounds new Alzheimer's drugs
For defenders, the drugs represent a real chance to fight the disease. For detractors, they are a disappointment after a long line of costly failures.
U.K. authorities have approved lecanemab, a novel Alzheimer's drug developed by Eisai, making Britain the first country in Europe to greenlight the drug.
JAPAN
Aug 23, 2024
Britain OKs Eisai's novel Alzheimer's drug lecanemab
The United Kingdom is the first country in Europe to greenlight the drug.
A health ministry panel has approved Eli Lilly's donanemab drug for Alzheimer's patients.
JAPAN / Science & Health
Aug 2, 2024
Japan's health ministry set to approve second Alzheimer's drug
Donanemab, developed by U.S. pharmaceutical firm Eli Lilly, has been backed by a ministry panel.
A scientist looks at scans at the Memory Center at the Department of Readaptation and Geriatrics of the University Hospital in Geneva on June 6, 2023.
WORLD / Science & Health
Jul 29, 2024
A blood test accurately diagnosed Alzheimer’s 90% of the time, study finds
A team of researchers reported that a blood test was significantly more accurate than doctors’ interpretation of cognitive tests and CT scans in signaling Alzheimer's.
The latest research indicates that heat stress is likely to worsen the condition of people with Alzheimer’s disease — which accounts for over half of all dementia cases in Japan — by making them more irritated or exacerbating their cognitive decline.
JAPAN / Science & Health / Boiling Point
Jul 29, 2024
For aging Japan, a troubling link between heat and dementia
The latest research indicates that heat can exacerbate cognitive decline and worsen dementia symptoms.
Leqembi, which was developed by U.S. multinational Biogen and Japanese-based Eisai, is the brand name of an active substance called lecanemab, which is used to treat adults with mild memory and cognitive problems resulting from the early stages of the common type of dementia.
JAPAN / Science & Health
Jul 27, 2024
European medicines watchdog rejects Eisai's new Alzheimer's drug
The watchdog said the risks of side effects, including potential brain bleeding, outweighed the benefits.
Researchers at Tokyo's Juntendo University investigated whether an SGLT2 inhibitor, a drug that promotes sugar excretion through urine, could remove aging cells by administering it to obese mice for a week.
JAPAN / Science & Health
May 31, 2024
Diabetes drug shows promise for aging-related illnesses in mice study
The Juntendo University study shows an SGLT2 inhibitor successfully eliminating senescent cells, which accumulate with age, in the mice's visceral fat.
The latest findings by University of Tokyo researchers raise hopes that the disease may be treated if doctors can identify people who will develop Alzheimer’s before its onset.
JAPAN / Science & Health
May 23, 2024
Japanese researchers confirm blood test predicts risk of Alzheimer's
The latest study raises hopes that if doctors can identify who might be at risk of developing Alzheimer’s beforehand, it could be treated early.
The latest figure is significantly less than a previous projection released in 2015 that said more than 8 million people would have dementia by 2040.
JAPAN / Science & Health
May 8, 2024
Nearly 6 million elderly people in Japan will have dementia by 2040
While the figure is lower than a previous projection, the latest estimate still showed a steady growth in the number of people with dementia.
Tests for patients suffering from Alzheimer's disease. According to the Alzheimer's Association, the disease is estimated to affect more than 6 million Americans.
WORLD / Science & Health / FOCUS
Apr 24, 2024
Alzheimer's drug adoption in U.S. slowed by doctors' skepticism
There is an entrenched belief among some doctors that treating the memory-robbing disease is futile.
JAPAN / Science & Health
Mar 15, 2024
Japan starts clinical trial of familial Alzheimer's treatment
The clinical trial is under way in 16 countries, with four people in their 30s to 50s participating in Japan.
Eisai's Alzheimer's drug Leqembi
BUSINESS / Companies
Feb 5, 2024
Eisai sees 'huge' growth potential for Alzheimer's drug in China
The Japanese pharmaceutical firm aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year.
Shitsui Hakoishi, 107, works with researcher Yasumichi Arai (left) while her younger brother, Hidemasa, looks on. Researchers like Arai believe the healthy and active Hakoishi's cells may hold the secret to living a long life.
JAPAN / Science & Health / Longform
Jan 27, 2024
Living until 100, if not forever, in good health
Immortality may be out of reach, but can a slew of research projects prolong our natural aging process?
JAPAN / Science & Health
Sep 25, 2023
As Japan OKs Alzheimer's drug, issue of side effects comes into focus
There are big challenges ahead for the use of lecanemab, particularly on how to control side effects such as brain swelling and bleeding.
Japan eyes tougher rules for foreign residents and tax hike for tourists
A tax-free shop in Kyoto in April 2024. Last week, members of a Liberal Democratic Party study group drafted a proposal seeking to scrap the country's tax-free shopping system altogether.
From ridicule to redemption: Rice crisis returns Koizumi to the spotlight
Agriculture minister Shinjiro Koizumi speaks to the media as he inspects a warehouse storing stockpiled rice in Kanagawa Prefecture on May 30.
Hakuho’s departure highlights worrying sumo trend
Former <i>yokozuna</i> Hakuho performs a ring-entering ceremony at the Ryogoku Kokugikan in Tokyo in February 2020.
Trump and Musk trade barbs on social media as alliance crumbles
The trouble between U.S. President Donald Trump and Elon Musk started brewing days ago, when Musk denounced Trump's sweeping tax-cut and spending bill.
How Japan's youth are slowly changing the country's work ethic
After the asset-price bubble crash of the early 1990s, employment at a Japanese company was no longer necessarily for life. As a result, a new generation is less willing to endure a toxic work culture —life’s too short, after all.
New Naoshima museum bets on Asia, not the West
Detail of Takashi Murakami, “Rakuchu-Rakugai-zu Byobu: Iwasa Matabei RIP” (2023-25)
Japan’s prison reform focuses on rehabilitation
Justice Minister Keisuke Suzuki speaks to reporters in Tokyo on Friday. Suzuki said preparations for the changes that will focus more on rehabilitation are being actively made at each correctional facility.
Six months into 2025, J-pop is having a full-on identity crisis (and a great time)
The year so far is only proving that Mrs. Green Apple is the biggest band in Japan. Their success also seems to be hinting at a change in the musical landscape more broadly.
Nintendo’s Switch 2 console is finally here
The Switch 2 is Nintendo's first new gaming console in eight years.
Hakuho’s departure highlights worrying sumo trend
Former <i>yokozuna</i> Hakuho performs a ring-entering ceremony at the Ryogoku Kokugikan in Tokyo in February 2020.

Podcast

One of the many entrances to the Kabukicho neighborhood in Tokyo’s Shinjuku Ward.
Kabukicho: Tokyo’s ‘stadium of desire’

Longform

After the asset-price bubble crash of the early 1990s, employment at a Japanese company was no longer necessarily for life. As a result, a new generation is less willing to endure a toxic work culture —life’s too short, after all.
How Japan's youth are slowly changing the country's work ethic
By Alex K.T. Martin

SUSTAINABLE JAPAN

Smile! It’s ‘Sanrio Time,’ now and ever after
Smile! It’s ‘Sanrio Time,’ now and ever after

SPECIAL SUPPLEMENTS note

Read more

SUPPLEMENTS BINDER